The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Open accessAbstract
Meta-analyses conducted >15 years ago reported that improvements in bone mineral density (BMD) were associated with reduction in vertebral and nonvertebral fractures in osteoporosis trials. Numerous studies have been conducted since then, incorporating new therapies with different mechanisms of action and enrolling many more subjects. To extend these prior analyses, we conducted a meta-regression of 38 placebo-controlled trials of 19 therapeutic agents to determine the association between improvements in BMD and reductions in fracture risk. We used a linear model to examine the relationship between mean percent difference in BMD change between treatment and placebo groups and the logarithm of the relative risk. We found that greater improvements in BMD were strongly associated with greater reductions in vertebral and hip fractures but not nonvertebral fractures. For vertebral fracture, the r2 values for total hip, femoral neck, and lumbar spine BMD change were 0.56, 0.54, and 0.63, respectively (p ≤ 0.0002). For a 2% or 6% improvement in total hip BMD, we might expect a 28% or 66% reduction, respectively, in vertebral fracture risk. For hip fracture, the r2 values for total hip, femoral neck, and lumbar spine BMD change were 0.48 (p = 0.01), 0.42 (p = 0.02), and 0.22 (ns), respectively. For a 2% or 6% improvement in total hip BMD, we might expect a 16% or 40% reduction in hip fracture risk. In conclusion, our results extend prior observations that larger improvements in dual-energy X-ray absorptiometry (DXA)-based BMD are associated with greater reductions in fracture risk, particularly for vertebral and hip fractures. Although these results cannot be directly applied to predict the treatment benefit in an individual patient, they provide compelling evidence that improvements in BMD with osteoporosis therapies may be useful surrogate endpoints for fracture in trials of new therapeutic agents. © 2019 American Society for Bone and Mineral Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationDenosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationHarris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475 · cited 11×
“bisphosphonates (20 trials), four SERMs (5 trials), calcitonin, estrogen compounds (2 trials), tibolone (1 trial), anti-Rank Ligand antibody (2 trials), PTH(1-84) (1 trial), two PTH analogs (4 trials), anti-sclerostin antibody (1 trial), and a cathepsin K inhibitor (1 trial).”
BackgroundMethodInfluentialLiberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003 · cited 12×
“60 (13) Greenspan (2007)((15)) PTH(1-84) 2.”
BackgroundInfluentialEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationRomosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citationBlack, D. M., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1513724 · Cited by 1,712
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationRomosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708322 · Cited by 1,544
Self-citationChesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Cauley, J. A. (2003) · JAMA · doi:10.1001/jama.290.13.1729 · Cited by 1,221
Self-citationChesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Self-citationAlendronate for the Treatment of Osteoporosis in Men
Orwoll, E., Ettinger, M., Weiss, S., Miller, P., Kendler, D., Graham, J., Adami, S., Weber, K., Lorenc, R., Pietschmann, P., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430902 · Cited by 973
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., Yanover, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 949
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Miller, P. D., Hattersley, G., Riis, B. J., Williams, G. C., Lau, E., Russo, L. A., Alexandersen, P., Zerbini, C. A. F., Hu, M.-Y., Harris, A. G., et al. (2016) · JAMA · doi:10.1001/jama.2016.11136 · Cited by 875
Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01124-x · Cited by 752
Self-citationPols, H. A. P., Felsenberg, D., Hanley, D. A., Štepán, J., Muñoz-Torres, M., Wilkin, T. J., Qin-sheng, G., Galich, A. M., Vandormael, K., Yates, A. J., et al. (1999) · Osteoporosis International · doi:10.1007/pl00004171 · Cited by 593
Silverman, S. L., Christiansen, C., Genant, H. K., Vukicevic, S., Zanchetta, J. R., de Villiers, T. J., Constantine, G. D., & Chines, A. A. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080710 · Cited by 508
Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age
Hosking, D., Chilvers, C. E. D., Christiansen, C., Ravn, P., Wasnich, R., Ross, P., McClung, M., Balske, A., Thompson, D., Daley, M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802193380801 · Cited by 488
Hochberg, M. C. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1586 · Cited by 480
The Effects of Tibolone in Older Postmenopausal Women
Cummings, S. R., Ettinger, B., Delmas, P. D., Kenemans, P., Stathopoulos, V., Verweij, P., Mol-Arts, M., Kloosterboer, L., Mosca, L., Christiansen, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800743 · Cited by 457
Self-citationGreenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R., Zanchetta, J. R., Blosch, C. M., Mathisen, A. L., Morris, S. A., Marriott, T. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00005 · Cited by 427
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., & San Martin, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2814 · Cited by 425
Lasofoxifene in Postmenopausal Women with Osteoporosis
Cummings, S. R., Ensrud, K., Delmas, P. D., LaCroix, A. Z., Vukicevic, S., Reid, D. M., Goldstein, S., Sriram, U., Lee, A., Thompson, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0808692 · Cited by 387
Self-citationGreenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R. S., Zanchetta, J., Blosch, C. M., Mathisen, A. L., Morris, S. A., & Marriott, T. B. (2007) · Annals of Internal Medicine · Cited by 360
Fracture risk and zoledronic acid therapy in men with osteoporosis
Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204061 · Cited by 359
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · Obstetrical and Gynecological Survey · doi:10.1097/00006254-200110000-00018 · Cited by 305
Benefits and risks of bisphosphonate therapy for osteoporosis
Khosla, S., Bilezikian, J. P., Dempster, D. W., Lewiecki, E. M., Miller, P. D., Neer, R. M., Recker, R. R., Shane, E., Shoback, D., & Potts, J. T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1027 · Cited by 290
Alendronate and Estrogen Effects in Postmenopausal Women with Low Bone Mineral Density
Bone, H. G. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.720 · Cited by 277
Nakamura, T., Sugimoto, T., Nakano, T., Kishimoto, H., Ito, M., Fukunaga, M., Hagino, H., Sone, T., Yoshikawa, H., Nishizawa, Y., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3479 · Cited by 268
Jackson, R. D., Wactawski-Wende, J., LaCroix, A. Z., Pettinger, M., Yood, R. A., Watts, N. B., Robbins, J. A., Lewis, C. E., Beresford, S. A., Ko, M. G., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060312 · Cited by 239
McCloskey, E. V., Beneton, M., Charlesworth, D., Kayan, K., de Takats, D., Dey, A., Orgee, J., Ashford, R., Forster, M., Cliffe, J., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061008 · Cited by 200
Fogelman, I., Ribot, C., Smith, R., Ethgen, D., Sod, E., & Reginster for the bmd-mn Study Grou, J.-Y. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.5.6603 · Cited by 198
Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women1
Bone, H. G., Downs, R. W., Tucci, J. R., Harris, S. T., Weinstein, R. S., Licata, A. A., McClung, M. R., Kimmel, D. B., Gertz, B. J., Hale, E., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3682 · Cited by 189
Recker, R., Stakkestad, J. A., Chesnut, C. H., Christiansen, C., Skag, A., Hoiseth, A., Ettinger, M., Mahoney, P., Schimmer, R. C., & Delmas, P. D. (2004) · Bone · doi:10.1016/j.bone.2004.01.008 · Cited by 172
Nakamura, T., Matsumoto, T., Sugimoto, T., Hosoi, T., Miki, T., Gorai, I., Yoshikawa, H., Tanaka, Y., Tanaka, S., Sone, T., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4175 · Cited by 170
Paschalis, E. P., Glass, E. V., Donley, D. W., & Eriksen, E. F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2489 · Cited by 160
Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women
Greenspan, S. L., Perera, S., Ferchak, M. A., Nace, D. A., & Resnick, N. M. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.0747 · Cited by 145
McCloskey, E. V., Selby, P. L., Davies, M., Robinson, J., Francis, R. M., Adams, J. E., Kayan, K., Beneton, M. N. C., Jalava, T., Pylkkänen, L. H., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040116 · Cited by 145
Greenspan, S. L., Schneider, D. L., McClung, M. R., Miller, P. D., Schnitzer, T. J., Bonin, R., Smith, M. E., DeLucca, P. T., Gormley, G. J., & Melton, M. E. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-10-200205210-00009 · Cited by 126
Rate and circumstances of clinical vertebral fractures in older men
Freitas, S. D. S., Barrett-Connor, E. L., Ensrud, K. E., Fink, H. A., Bauer, D. C., Cawthon, P. M., Lambert, L. C., & ORWOLL, E. S. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0510-1 · Cited by 116
Self-citationArzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women
Cummings, S. R., McClung, M. R., Reginster, J., Cox, D., Mitlak, B., Stock, J. L., Amewou-Atisso, M. G., Powles, T. J., Miller, P. D., Zanchetta, J., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.191 · Cited by 111
Reid, I. R., Eastell, R., Fogelman, I., Adachi, J. D., Rosen, A. S., Netelenbos, J. C., Watts, N. B., Seeman, E., Ciaccia, A. V., & Draper, M. W. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.8.871 · Cited by 79
Self-citationMorii, H., Ohashi, Y., Taketani, Y., Fukunaga, M., Nakamura, T., Itabashi, A., Sarkar, S., & Harper, K. D. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1424-1 · Cited by 78
Nakamura, T., Fukunaga, M., Nakano, T., Kishimoto, H., Ito, M., Hagino, H., Sone, T., Taguchi, A., Tanaka, S., Ohashi, M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3736-y · Cited by 78
Bauer, D. C., Black, D. M., Bouxsein, M., Lui, L., Cauley, J. A., de Papp, A. E., Grauer, A., Khosla, S., McCulloch, C. E., & Eastell, R. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3355 · Cited by 77
Self-citationBouxsein, M., & Delmas, P. D. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080301 · Cited by 73
Self-citationBonnick, S. L., Villiers, T. D., Odio, A., Palacios, S., Chapurlat, R. D., DaSilva, C. A., Scott, B. B., Tilleghem, C. L. B. D., LEUNG, A. T., & Gurner, D. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2020 · Cited by 59
Hooper, M. J., Ebeling, P. R., Roberts, A. P., Graham, J. J., Nicholson, G. C., dʼEmden, M. C., Ernst, T. F., & Wenderoth, D. (2005) · Climacteric · doi:10.1080/13697130500118126 · Cited by 55
Itabashi, A., Yoh, K., Chines, A. A., Miki, T., Takada, M., Satō, H., Gorai, I., Sugimoto, T., Mizunuma, H., Ochi, H., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.252 · Cited by 42
Fujita, T., Fukunaga, M., Itabashi, A., Tsutani, K., & Nakamura, T. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9777-8 · Cited by 30
Yan, Y., Wang, W., Zhu, H.-M., Li, M., Liu, J., Bangyao, L., Xie, H., Zhang, G., & Li, F. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0057-7 · Cited by 27
Cited by
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Long-term and sequential treatment for osteoporosis
Foessl, I., Dimai, H. P., & Obermayer-Pietsch, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00866-9 · Cited by 273
Black, D. M., Bauer, D. C., Vittinghoff, E., Lui, L.-Y., Grauer, A., Marin, F., Khosla, S., de Papp, A., Mitlak, B., Cauley, J. A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30159-5 · Cited by 228
Self-citationMenopausal hormone therapy for the management of osteoporosis
Gosset, A., Pouillès, J.-M., & Trémollieres, F. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101551 · Cited by 193
Metadata
- Authors
- Bouxsein, M. L., Eastell, R., Lui, L.-Y., Wu, L. A., de Papp, A. E., Grauer, A., Marin, F., Cauley, J. A., Bauer, D. C., Black, D. M., & for the FNIH Bone Quality Project
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-23
- Volume
- 34
- Issue
- 4
- Pages
- 632-642
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2912416377
- Cited by
- 353
- References
- 59
- FWCI
- 37.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.